The abstract is read at the publisher; the summary is JClub's.
Vosoritide treatment in children with hypochondroplasia is linked to sustained growth gains over three years, with mean height SDS rising by 0.72 SD to -2.64±0.79.
- Why it matters: The study addresses the need to understand long-term safety and whether early growth responses persist in hypochondroplasia, a selected genetic cause of short stature.
- What they did: In a phase 2 open-label extension, 13 participants who showed AGV increase >1.6 cm/year after 6 months observation plus 12 months of daily subcutaneous vosoritide (15 μg/kg/day) continued treatment for three years.
- The result: Mean AGV increased from 4.27±0.70 cm/year at baseline to 7.24±0.80 at Year 1 and stayed above baseline at Year 3 (6.13±1.27), with no new safety concerns identified.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.